Cargando…
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Multiple immunotherapeutic approaches have been investigated to date, and immunotherapy has become the new standard of care therapy in HCC. However, the current role of...
Autores principales: | Gok Yavuz, Betul, Hasanov, Elshad, Lee, Sunyoung S, Mohamed, Yehia I, Curran, Michael A, Koay, Eugene J, Cristini, Vittorio, Kaseb, Ahmed O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478438/ https://www.ncbi.nlm.nih.gov/pubmed/34595140 http://dx.doi.org/10.2147/JHC.S322289 |
Ejemplares similares
-
Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2022) -
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma
por: Gok Yavuz, Betul, et al.
Publicado: (2023) -
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
por: Mamdani, Hirva, et al.
Publicado: (2022) -
Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
por: Yavuz, Betul Gok, et al.
Publicado: (2020) -
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)